VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany

Completed

Conditions: HIV Infections

Interventions: Other: HIV Symptom Distress Module Questionnaire
Other: HIV treatment satisfaction questionnaire

First Posted Date: 2018-11-27

Last Posted Date: 2024-07-15

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 366

Registration Number: NCT03754803

Locations: 🇩🇪
GSK Investigational Site, Weimar, Germany

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

Phase 3

Active, not recruiting

Conditions: HIV Infections

Interventions: Drug: DTG + 3TC FDC

First Posted Date: 2018-09-25

Last Posted Date: 2024-08-29

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 32

Registration Number: NCT03682848

Locations: 🇹🇭
GSK Investigational Site, Chiang Mai, Thailand

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: RPV
Drug: CAB LA
Drug: RPV LA
Drug: DTG

First Posted Date: 2018-08-21

Last Posted Date: 2024-06-11

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 97

Registration Number: NCT03639311

Locations: 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada

A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GSK3640254 bis-hydrochloride salt capsule
Drug: GSK3640254 Mesylate Salt Capsule

First Posted Date: 2018-07-03

Last Posted Date: 2019-09-06

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 14

Registration Number: NCT03575962

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women

Recruiting

Conditions: HIV Infections

Interventions: Drug: DTG

First Posted Date: 2018-06-21

Last Posted Date: 2024-05-17

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 250

Registration Number: NCT03564613

Locations: 🇪🇸
GSK Investigational Site, Barcelona, Spain

Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1

Completed

Conditions: HIV Infections

Interventions: Drug: JULUCA

First Posted Date: 2018-05-08

Last Posted Date: 2024-10-16

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 209

Registration Number: NCT03518060

Locations: 🇩🇪
GSK Investigational Site, Weimar, Germany

GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

Conditions: Infection, Human Immunodeficiency Virus

First Posted Date: 2018-03-13

Last Posted Date: 2021-05-21

Lead Sponsor: ViiV Healthcare

Registration Number: NCT03462810

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: TAF based regimen (TBR)
Drug: DTG + 3TC

First Posted Date: 2018-02-27

Last Posted Date: 2023-07-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 743

Registration Number: NCT03446573

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Treatment A
Drug: Treatment D
Drug: Treatment B
Drug: Treatment E
Drug: Treatment C
Drug: Treatment F

First Posted Date: 2018-02-22

Last Posted Date: 2019-12-09

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 36

Registration Number: NCT03441984

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Oral CAB
Drug: CAB LA

First Posted Date: 2018-02-05

Last Posted Date: 2021-05-13

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 48

Registration Number: NCT03422172

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy